Background: Exposure of human basophils to allergens results in a rapid secretion of histamine, LTC4, IL-4 and IL-13, which dominate both the symptomology of allergic diseases and support the underlying Th2/IgE predominance associated with these reactions. The IgE-dependent release of these mediators in basophils crucially involves PI 3-kinase and the subsequent activation of p38 MAPK and ERK1&2. Here, we investigated the role of the third major member of the mitogen activated kinase family, namely the c-Jun amino terminal kinase (JNK), which is rapidly activated following IgE receptor cross-linking in murine mast cells. Methods: Human basophils were highly purified by magnetic cell sorting. The activities of various intracellular signaling components, in basophils that had been stimulated under various conditions, were assessed by Western blotting. Mediator secretions were also determined using either spectrofluorometric analysis (histamine) or ELISA (LTC4, IL-4 and IL-13). Results: Our results show that while JNK is moderately expressed in human basophils, it is not consistently phosphorylated upon anti-IgE stimulation. Phosphorylation of the transcription factor c-Jun, a downstream target of JNK, was also undetected in contrast to p38 MAPK and ERK1&2, which were clearly activated following anti-IgE stimulation of the cells. Additionally, inhibitors of the JNK pathway failed to prevent basophil mediator release and had no effect on the phosphorylation of p38 MAPK or ERK1&2 at concentrations which were specific for JNK blockade. Conclusions: These data suggest major differences in utilizing various members of the mitogen-activated kinase family in the signal transduction cascade of IgE-receptor-bearing cells.

Keywords:
Basophils, Signal transduction, Inflammatory mediators, IgE
1.
Kepley CL, McFeeley PJ, Oliver J-M, Lipscomb MF: Immunohistochemical detection of human basophils in postmortem cases of fatal asthma. Am J Respir Crit Care Med 2001;164:1053–1058.
2.
Guo CB, Liu MC, Galli SJ, Bochner BS, Kagey-Sobotka A, Lichtenstein LM: Identification of IgE bearing cells in the late response to antigen in the lung as basophils. Am J Respir Cell Mol Biol 1993;10:384–390.
3.
Maruyama N, Tamura G, Aizawa T, Ohrui T, Shimura S, Shirato K, Takishima T: Accumulation of basophils and their chemotactic activity in the airways during natural airway narrowing in asthmatic individuals. Am J Crit Care Med 1994;150:1086–1093.
4.
Bascom R, Wachs M, Naclerio RM, Pipkorn U, Galli SJ, Lichtenstein LM: Basophil influx occurs after nasal antigen challenge: Effects of topical corticosteroid pretreatment. J Allergy Clin Immunol 1988;81:580–589.
5.
Charlesworth EN, Hood AF, Soter NA, Kagey SA, Norman PS, Lichtenstein LM: Cutaneous late-phase response to allergen: Mediator release and inflammatory cell infiltration. J Clin Invest 1989;83:1519–1526.
6.
Schroeder JT, MacGlashan DW: New concepts: The basophil. J Allergy Clin Immunol 1997;99:429–433.
7.
Falcone FH, Haas H, Gibbs BF: The human basophil: A new appreciation of its role in immune responses. Blood 2000;96:4028–4038.
8.
Masinovsky B, Urdal D, Gallatin WM: IL-4 acts synergistically with IL-1β to promote lymphocyte adhesion to microvascular endothelium by induction of vascular cell adhesion molecule-1. J Immunol 1990;145:2886–2895.
9.
Bochner BS, Klunk DA, Sterbinsky SA, Coffman RL, Schleimer RP: IL-13 selectively induces vascular cell adhesion molecule-1 expression in human endothelial cells. J Immunol 1995;154:799–803.
10.
Haas H, Falcone FH, Holland MJ, Schramm G, Haisch K, Gibbs BF, Bufe A, Schlaak M: Early interleukin-4: Its role in the switch towards a Th2 response and IgE-mediated allergy. Int Arch Allergy Immunol 1999;119:86–94.
11.
Yanagihara Y, Kajiwara K, Basaki Y, Ikizawa K, Ebisawa M, Ra C, Tachimoto H, Saito H: Cultured basophils but not cultured mast cells induce human IgE synthesis in B cells after immunologic stimulation. Clin Exp Immunol 1998;111:136–143.
12.
Gibbs BF, Grabbe J: Inhibitors of PI 3-kinase and MEK kinase differentially affect mediator secretion from immunologically activated human basophils. J Leukoc Biol 1999;65:883–890.
13.
Miura K, MacGlashan DW: Phosphatidylinositol-3 kinase regulates p21ras activation during IgE-mediated stimulation of human basophils. Blood 2000;96:2199–2205.
14.
Miura K, Schroeder JT, Hubbard WC, MacGlashan DW: Extracellular signal-regulated kinases regulate leukotriene C4 generation, but not histamine release or IL-4 production from human basophils. J Immunol 1999;162:4198–4206.
15.
Gibbs BF, Plath KES, Wolff HH, Grabbe J: Regulation of mediator secretion in human basophils by p38 mitogen-activated protein kinase: Phosphorylation is sensitive to the effects of phosphatidylinositol 3-kinase inhibitors and calcium mobilization. J Leukoc Biol 2002;72:391–400.
16.
Ishizuka T, Terada N, Gerwins P, Hamelmann E, Oshiba A, Fanger GR, Johnson GL, Gelfand EW: Mast cell tumor necrosis factor alpha production is regulated by MEK kinases. Proc Natl Acad Sci USA 1997;94:6358–6363.
17.
Ishizuka T, Oshiba A, Sakata A, Johnson GL, Gelfand EW: Aggregation of the FcepsilonRI on mast cells stimulates c-Jun amino-terminal kinase activity. A response inhibited by wortmannin. J Biol Chem 1996;271:12762–12766.
18.
Kawakami Y, Hartman SE, Holland PM, Cooper JA, Kawakami T: Multiple signaling pathways for the activation of JNK in mast cells: Involvement of Bruton’s tyrosine kinase, protein kinase C, and JNK kinases, SEK1 and MKK7. J Immunol 1998;161:1795–1802.
19.
Haisch K, Gibbs BF, Körber H, Ernst M, Grage-Griebenow E, Schlaak M, Haas H: Purification of morphologically and functionally intact human basophils to near homogeneity. J Immunol Methods 1999;226:129–137.
20.
Bonny C, Oberson A, Negri S, Sauser C, Schorderet DF: Cell-permeable peptide inhibitors of JNK: Novel blockers of beta-cell death. Diabetes 2001;50:77–82.
21.
Han Z, Boyle DL, Chang L, Bennett B, Karin M, Yang L, Manning AM, Firestein GS: c-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis. J Clin Invest 2001;108:73–81.
22.
Ishizuka T, Chayama K, Takeda K, Hamelmann E, Terada N, Keller GM, Johnson GL, Gelfand EW: Mitogen-activated protein kinase activation through Fc epsilon receptor I and stem cell factor receptor is differentially regulated by phosphatidylinositol 3-kinase and calcineurin in mouse bone marrow-derived mast cells. J Immunol 1999;162:2087–2094.
23.
Kimata M, Inagaki N, Kato T, Miura T, Serizawa I, Nagai H: Roles of mitogen-activated protein kinase pathways for mediator release from human cultured mast cells. Biochem Pharmacol 2000;60:589–594.
24.
Azzolina A, Guarneri P, Lampiasi N: Involvement of p38 and JNK MAPKs pathways in substance P-induced production of TNF-alpha by peritoneal mast cells. Cytokine 2002;18:72–80.
25.
Barker SA, Caldwell KK, Hall A, Martinez AM, Pfeiffer JR, Oliver JM, Wilson BS: Wortmannin blocks lipid and protein kinase activities associated with PI 3-kinase and inhibits a subset of responses induced by Fc epsilon R1 cross-linking. Mol Biol Cell 1995;6:1145–1158.
26.
Kimura T, Hisano M, Inoue Y, Adachi M: Tyrosine phosphorylation of the linker for activator of T cells in mast cells by stimulation with the high affinity IgE receptor. Immunol Lett 2001;75:123–129.
27.
Knol EF, Koenderman L, Mul FPJ, Verhoeven AJ, Roos D: Differential activation of human basophils by anti-IgE and formyl-methionyl-leucyl-phenylalanine. Indications for protein kinase C-dependent and -independent activation pathways. Eur J Immunol 1991;21:881–885.
28.
Marquardt DL, Alongi JL, Walker LL: The phosphatidylinositol 3-kinase inhibitor wortmannin blocks mast cell exocytosis but not IL-6 production. J Immunol 1996;156:1942–1945.
29.
Hirasawa N, Sato Y, Fujita Y, Ohuchi K: Involvement of a phosphatidylinositol 3-kinase-p38 mitogen activated protein kinase pathway in antigen-induced IL-4 production in mast cells. Biochim Biophys Acta 2000;1456:45–55.
© 2005 S. Karger AG, Basel
2005
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.